Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 12:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 146 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Psoriasis Chronic Clear all
Completed No phase listed Observational

A Study to Evaluate Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE)

NCT00096928
View directory record Official record
Conditions
Psoriasis
Interventions
Not listed
Lead sponsor
Genentech, Inc.
Industry
Eligibility
Not listed
Enrollment
1,846 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
182
States / cities
Birmingham, Alabama • Daphne, Alabama • Gadsden, Alabama + 153 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2015 · Synced Oct 21, 2026, 12:56 AM EDT
Completed Phase 3 Interventional

A Study to Assess the Efficacy and Safety of Two Dosing Regimens of Alefacept in Subjects Weighing Between 100kg and 150kg With Moderate to Severe Chronic Plaque Psoriasis

NCT00674063
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
alefacept
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
11
States / cities
Hot Springs, Arkansas • Fridley, Minnesota • Omaha, Nebraska + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2014 · Synced Oct 21, 2026, 12:56 AM EDT
Completed Phase 4 Interventional Results available

Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet

NCT00735787
View directory record Official record
Conditions
Psoriasis
Interventions
Placebo, Adalimumab
Biological
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
8
States / cities
Little Rock, Arkansas • Bakersfield, California • Macon, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2010 · Synced Oct 21, 2026, 12:56 AM EDT
Completed Phase 1 Interventional

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of AbGn-168 in Psoriasis

NCT00848055
View directory record Official record
Conditions
Psoriasis
Interventions
AbGn168 intravenous infusion, AbGn168 subcutaneous injection
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
6
States / cities
Boise, Idaho • Evansville, Indiana • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2013 · Synced Oct 21, 2026, 12:56 AM EDT
Completed Phase 2 Interventional Results available

Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00678210
View directory record Official record
Conditions
Psoriasis
Interventions
CP-690,550, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
29
States / cities
Tucson, Arizona • Little Rock, Arkansas • Oceanside, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2012 · Synced Oct 21, 2026, 12:56 AM EDT
Completed Phase 4 Interventional Results available

Enstilar® Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color

NCT03506477
View directory record Official record
Conditions
Plaque Psoriasis, Psoriasis
Interventions
Enstilar® foam, Vehicle foam
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Oct 21, 2026, 12:56 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis

NCT03010527
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
Bimekizumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
8
States / cities
Los Angeles, California • Washington D.C., District of Columbia • West Des Moines, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Oct 21, 2026, 12:56 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Secukinumab in Mild Psoriasis

NCT03131570
View directory record Official record
Conditions
Psoriasis
Interventions
Secukinumab, Placebo followed by Secukinumab
Drug
Lead sponsor
James G. Krueger, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 21, 2022 · Synced Oct 21, 2026, 12:56 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00235820
View directory record Official record
Conditions
Psoriasis
Interventions
adalimumab, MTX, placebo adalimumab, placebo MTX
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Abbott Park, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 17, 2008 · Synced Oct 21, 2026, 12:56 AM EDT
Withdrawn Phase 2 Interventional

Apremilast for Chronic Plaque Psoriasis (CPP) Patients Who Have Failed One Course of Biologic Therapy

NCT01200264
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
apremilast
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 15, 2014 · Synced Oct 21, 2026, 12:56 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO)

NCT03766685
View directory record Official record
Conditions
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
Interventions
Bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
27
States / cities
Phoenix, Arizona • Bakersfield, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Oct 21, 2026, 12:56 AM EDT
Completed Phase 2 Interventional Results available

The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis

NCT03638258
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Roflumilast Cream 0.3%, Roflumilast Cream 0.15%, Vehicle Cream
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
20
States / cities
Beverly Hills, California • Northridge, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2022 · Synced Oct 21, 2026, 12:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Vitamin D and Fish Oil for Autoimmune Disease, Inflammation and Knee Pain

NCT01351805
View directory record Official record
Conditions
Autoimmune Diseases, Systemic Inflammatory Process, Knee Pain Chronic, Osteoarthritis, Rheumatoid Arthritis
Interventions
Fish Oil, Vitamin D, placebo pill
Drug · Dietary Supplement · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older
Enrollment
25,871 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 21, 2026, 12:56 AM EDT
Completed Phase 4 Interventional Results available

Mechanism of Action Study for Psoriasis

NCT00932113
View directory record Official record
Conditions
Psoriasis
Interventions
Methotrexate, Adalimumab (Humira)
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Oct 21, 2026, 12:56 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Prurisol Administered Orally for Active Moderate to Severe Chronic Plaque Psoriasis

NCT02949388
View directory record Official record
Conditions
Chronic Stable Plaque Psoriasis
Interventions
Placebo, 400 mg (200 mg BID), 300 mg (150 mg BID)
Drug
Lead sponsor
Innovation Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
34
States / cities
Glendale, Arizona • Hot Springs, Arkansas • Rogers, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Oct 21, 2026, 12:56 AM EDT
Terminated Phase 3 Interventional Results available

A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

NCT01163253
View directory record Official record
Conditions
Psoriasis
Interventions
CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
2,867 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
101
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Oct 21, 2026, 12:56 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Severe Psoriasis

NCT00954915
View directory record Official record
Conditions
Psoriasis
Interventions
teplizumab
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Ann Arbor, Michigan • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Oct 21, 2026, 12:56 AM EDT
Completed Phase 4 Interventional Results available

Long-Term One Year Use of Alefacept (Amevive®) in Moderate to Severe Chronic Plaque Type Psoriasis

NCT00655564
View directory record Official record
Conditions
Psoriasis
Interventions
Alefacept
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Oct 21, 2026, 12:56 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT03412747
View directory record Official record
Conditions
Chronic Plaque Psoriasis, Moderate to Severe Plaque Psoriasis
Interventions
Bimekizumab, Adalimumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
23
States / cities
Glendale, Arizona • Los Angeles, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 21, 2026, 12:56 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens

NCT01406938
View directory record Official record
Conditions
Moderate to Severe Plaque-type Psoriasis
Interventions
AIN457 150mg, AIN457 300mg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
967 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
33
States / cities
Fresno, California • Pasadena, California • Sacramento, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 19, 2015 · Synced Oct 21, 2026, 12:56 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis

NCT02267135
View directory record Official record
Conditions
Chronic Scalp Psoriasis
Interventions
Secukinumab 300 mg, Placebo
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
17
States / cities
Sacramento, California • Aurora, Colorado • Trumbull, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 21, 2026, 12:56 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis

NCT02905006
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
Bimekizumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
11
States / cities
Fremont, California • Los Angeles, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 21, 2026, 12:56 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis

NCT02850965
View directory record Official record
Conditions
Psoriasis
Interventions
BI 695501, Humira
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
14
States / cities
Anniston, Alabama • Phoenix, Arizona • Santa Ana, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2019 · Synced Oct 21, 2026, 12:56 AM EDT
Completed Phase 3 Interventional Results available

A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis

NCT01186744
View directory record Official record
Conditions
Psoriasis
Interventions
CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
666 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
50
States / cities
Mobile, Alabama • Tucson, Arizona • Fremont, California + 33 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2018 · Synced Oct 21, 2026, 12:56 AM EDT